RE: MoneyWeek3 Apr 2020 12:20
See broker note - We reiterate our rNPV-based target price of 120p, of which c.80p relates to the use of SNG001 in COVID-19 disease.
A 25% uplift on 40p gives 50p. That appears about correct given the probability of the trials being successful.